In vitro activity of tigecycline and comparators against gram-negative bacteria isolated from a tertiary hospital in Alexandria, Egypt

Microbial Drug Resistance

Volumn 17, Issue 4, 2011, Pages 489-495

  Mohamed, Nelly M ^a   Youssef, Alaa A F ^a  

^a Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; BIOFILM; EGYPT; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; BIOFILMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EGYPT; ESCHERICHIA COLI; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITALS, TEACHING; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE;

EID: 82555183088     PISSN: 10766294     EISSN: 19318448     Source Type: Journal    
DOI: 10.1089/mdr.2010.0195     Document Type: Article

References (36)

1. Appleman, M.D., H. Belzberg, D.M. Citron, P.N. Heseltine, A.E. Yellin, J. Murray, and T.V. Berne. 2000. In vitro activities of nontraditional antimicrobials against multiresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak. Antimicrob. Agents Chemother. 44:1035-1040. (Pubitemid 30165287)
2. Betriu, C., I. Rodriguez-Avial, B.A. Sanchez, M. Gomez, J. Alvarez, and J.J. Picazo. 2002. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain. Antimicrob. Agents Chemother. 46:892-895. (Pubitemid 34157684)
3. Bradford, P.A., P.J. Petersen, M. Young, C.H. Jones, M. Tischler, and J. O'Connell. 2005. Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method. Antimicrob. Agents Chemother. 49:3903-3909. (Pubitemid 41233048)
4. Bratu, S., P. Tolaney, U. Karumudi, J. Quale, M. Mooty, S. Nichani, and D. Landman. 2005. Carbapenemaseproducing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J. Antimicrob. Chemother. 56:128-132. (Pubitemid 41418346)
5. CLSI. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Dean, C.R., M.A. Visalli, S.J. Projan, P.E. Sum, and P.A. Bradford. 2003. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob. Agents Chemother. 47:972-978. (Pubitemid 36254223)
7. Dobinsky, S., K. Kiel, H. Rohde, K. Bartscht, J.K. Knobloch, M.A. Horstkotte, and D. Mack. 2003. Glucose-related dissociation between icaADBC transcription and biofilm expression by Staphylococcus epidermidis: evidence for an additional factor required for polysaccharide intercellular adhesin synthesis. J. Bacteriol. 185:2879-2886. (Pubitemid 36514599)
8. Giamarellou, H., A. Antoniadou, and K. Kanellakopoulou. 2008. Acinetobacter baumannii: a universal threat to public health? Int. J. Antimicrob. Agents. 32:106-119.
9. Gootz, T.D. 2010 The global problem of antibiotic resistance. Crit. Rev. Immunol. 30:79-93.
10. Hill, D., B. Rose, A. Pajkos, M. Robinson, P. Bye, S. Bell, M. Elkins, B. Thompson, C. Macleod, S.D. Aaron, and C. Harbour. 2005. Antibiotic susceptibilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. J. Clin. Microbiol. 43:5085-5090. (Pubitemid 41484009)
11. Jaccard, C., N. Troillet, S. Harbarth, G. Zanetti, D. Aymon, R. Schneider, R. Chiolero, B. Ricou, J. Romand, O. Huber, P. Ambrosetti, G. Praz, D. Lew, J. Bille, M.P. Glauser, and A. Cometta. 1998. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob. Agents Chemother. 42:2966-2972. (Pubitemid 28501234)
12. Jean, S.S., L.J. Teng, P.R. Hsueh, S.W. Ho, and K.T. Luh. 2002. Antimicrobial susceptibilities among clinical isolates of extended-spectrum cephalosporin-resistant Gram-negative bacteria in a Taiwanese University Hospital. J. Antimicrob. Chemother. 49:69-76.
13. Kallel, H., M. Bahloul, L. Hergafi, M. Akrout, W. Ketata, H. Chelly, C.B. Hamida, N. Rekik, A. Hammami, and M. Bouaziz. 2006. Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. Int. J. Antimicrob. Agents. 28:366-369. (Pubitemid 44403003)
14. Karageorgopoulos, D.E., T. Kelesidis, I. Kelesidis, and M.E. Falagas. 2008. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J. Antimicrob. Chemother. 62:45-55. (Pubitemid 351865873)
15. Kelesidis, T., D.E. Karageorgopoulos, I. Kelesidis, and M.E. Falagas. 2008. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J. Antimicrob. Chemother. 62:895-904.
16. Landman, D., C. Georgescu, D.A. Martin, and J. Quale. 2008. Polymyxins revisited. Clin. Microbiol. Rev. 21:449-465.
17. Landman, D., S. Bratu, S. Kochar, M. Panwar, M. Trehan, M. Doymaz, and J. Quale. 2007. Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae in Brooklyn, NY. J. Antimicrob. Chemother. 60:78-82. (Pubitemid 47073279)
18. Lautenbach, E. 2009. Antimicrobial resistance in Gramnegative pathogens: crafting the tools necessary to navigate the long ascent out of the abyss. J. Infect. Dis. 200: 838-840.
19. Lewis, K. 2001. Riddle of biofilm resistance. Antimicrob. Agents Chemother. 45:999-1007. (Pubitemid 32230975)
20. Li, J., C.R. Rayner, R.L. Nation, R.J. Owen, D. Spelman, K.E. Tan, and L. Liolios. 2006. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 50:2946-2950. (Pubitemid 44396396)
21. Livermore, D.M. 2005. Tigecycline: what is it, and where should it be used? J. Antimicrob. Chemother. 56:611-614. (Pubitemid 41487758)
22. Livermore, D.M. 2009. Has the era of untreatable infections arrived? J. Antimicrob. Chemother. 64 Suppl 1:i29-i36.
23. Mallick, R., S. Sun, and S.R. Schell. 2007. Predictors of efficacy and health resource utilization in treatment of complicated intra-abdominal infections: evidence for pooled clinical studies comparing tigecycline with imipenem-cilastatin. Surg. Infect. (Larchmt). 8:159-172.
24. Morck, D.W., K. Lam, S.G. McKay, M.E. Olson, B. Prosser, B.D. Ellis, R. Cleeland, and J.W. Costerton. 1994. Comparative evaluation of fleroxacin, ampicillin, trimethoprimsulfamethoxazole, and gentamicin as treatments of catheter-associated urinary tract infection in a rabbit model. Int. J. Antimicrob. Agents. 4 Suppl 2:S21-S27. (Pubitemid 24248845)
25. Müsken, M., S. Di Fiore, U. Römling, and S. Häussler. 2010. A 96-well-plate-based optical method for the quantitative and qualitative evaluation of Pseudomonas aeruginosa biofilm formation and its application to susceptibility testing. Nat. Protoc. 5:1460-1469.
26. Navon-Venezia, S., A. Leavitt, and Y. Carmeli. 2007. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 59:772-774. (Pubitemid 47078722)
27. Owen, R.J., J. Li, R.L. Nation, and D. Spelman. 2007. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J. Antimicrob. Chemother. 59:473-477. (Pubitemid 47073453)
28. Pachon-Ibanez, M.E., M.E. Jimenez-Mejias, C. Pichardo, A.C. Llanos, and J. Pachon. 2004. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob. Agents Chemother. 48:4479-4481. (Pubitemid 39434923)
29. Pankey, G.A. 2005. Tigecycline. J. Antimicrob. Chemother. 56:470-480. (Pubitemid 41264122)
30. Passarell, J.A., A.K. Meagher, K. Liolios, B.B. Cirincione, S.A. Van Wart, T. Babinchak, E.J. Ellis-Grosse, and P.G. Ambrose. 2008. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob. Agents Chemother. 52:204-210.
31. Rodloff, A.C., E.J. Goldstein, and A. Torres. 2006. Two decades of imipenem therapy. J. Antimicrob. Chemother. 58:916-929.
32. Seifert, H., D. Stefanik, and H. Wisplinghoff. 2006. Comparative in vitro activities of tigecycline and 11 other antimicrobial agents against 215 epidemiologically defined multidrug-resistant Acinetobacter baumannii isolates. J. Antimicrob. Chemother. 58:1099-1100.
33. Souli, M., F.V. Kontopidou, E. Koratzanis, A. Antoniadou, E. Giannitsioti, P. Evangelopoulou, S. Kannavaki, and H. Giamarellou. 2006. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, Gram-negative and Gram-positive clinical isolates from Greek hospitals. Antimicrob. Agents Chemother. 50:3166-3169. (Pubitemid 44396429)
34. Souli, M., I. Galani, and H. Giamarellou. 2008. Emergence of extensively drug-resistant and pandrug-resistant Gramnegative bacilli in Europe. Euro. Surveill. 13:19045.
35. Talan, D.A. 2001. Clinical perspectives on new antimicrobials: focus on fluoroquinolones. Clin. Infect. Dis. 32 Suppl 1:S64-S71. (Pubitemid 32506748)
36. Vergidis, P.I., and M.E. Falagas. 2008. Multidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options. Curr. Opin. Investig. Drugs. 9:176-183. (Pubitemid 351206376)